MYC Degradation
Open accessThe DOI matches its Crossref record; 111 of the 114 references it cites were found in a registry or an index.
Abstract
The MYC oncoprotein is an essential transcription factor that regulates the expression of many genes involved in cell growth, proliferation, and metabolic pathways. Thus, it is important to keep MYC activity in check in normal cells in order to avoid unwanted oncogenic changes. Normal cells have adapted several ways to control MYC levels, and these mechanisms can be disrupted in cancer cells. One of the major ways in which MYC levels are controlled in cells is through targeted degradation by the ubiquitin-proteasome system (UPS). Here, we discuss the role of the UPS in the regulation of MYC protein levels and review some of the many proteins that have been shown to regulate MYC protein stability. In addition, we discuss how this relates to MYC transcriptional activity, human cancers, and therapeutic targeting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We show that DT-061 binds a unique heterotrimeric regulatory pocket to selectively stabilize the B56α-PP2A holoenzyme thereby inducing cell death and attenuating tumor growth through B56α directed substrate dephosphorylation, including its most well characterized substrate, the oncogenic protein c-MYC (Allen-Petersen et al., 2018; Arnold and Sears, 2006; Farrell and Sears, 2014; Sheppard et al., 2”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Farrell and Sears, 2014
Citations
Cites
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Self-citationc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Cited by
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
“Similarly, the specificity of targeting MYC protein stability is challenging 29 .”
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Huang, M., & Weiss, W. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014415 · Cited by 647
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 465
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Cancer stem cells, cancer cell plasticity and radiation therapy
Vlashi, E., & Pajonk, F. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.001 · Cited by 327
Target gene-independent functions of MYC oncoproteins
Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310
TERT—Regulation and Roles in Cancer Formation
Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T., & Bogunia-Kubik, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589929 · Cited by 311
“TheMYC gene family regulates expression of genes implicated in many processes, such as proliferation, cell growth, differentiation, self-renewal, apoptosis (91, 92).”
BackgroundThe MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 264
“MYC protein stability can be controlled in amulti-step process by RAS effector signaling (Farrell and Sears, 2014).”
BackgroundEmerging roles of aerobic glycolysis in breast cancer
Wu, Z., Wu, J., Zhao, Q., Fu, S., & Jin, J. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02187-8 · Cited by 255
The Expanding World of N-MYC–Driven Tumors
Rickman, D. S., Schulte, J. H., & Eilers, M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0273 · Cited by 241
“In primary neuroblasts, S62 is phosphorylated by CDK1, and therefore N-MYC degradation is initiated in mitosis (142).”
BackgroundElbadawy, M., Usui, T., Yamawaki, H., & Sasaki, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092340 · Cited by 234
“domain-containing (FBXW)7 target c-Myc for proteasomal degradation [133].”
BackgroundThe nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc
Sun, X.-X., He, X., Yin, L., Komada, M., Sears, R. C., & Dai, M.-S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411713112 · Cited by 221
“c-Myc is a short-lived protein in nontransformed cells that is degraded by the ubiquitin (Ub)- proteasome system (5, 6).”
BackgroundSelf-citationMYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 206
Archer, T. C., Ehrenberger, T., Mundt, F., Gold, M. P., Krug, K., Mah, C. K., Mahoney, E. L., Daniel, C. J., LeNail, A., Ramamoorthy, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.004 · Cited by 202
“Elevated pS62 and pT58 MYC suggest a breakdown in the canonical pathway of MYC degradation (Farrell and Sears, 2014), consistent with the increased expression of some kinases upstream of S62 phosphorylation as well as increased expression of deubiquitinating enzymes USP36 and USP28.”
Self-citationXia, P., Zhang, H., Lu, H., Xu, K., Jiang, X., Jiang, Y., Gongye, X., Chen, Z., Liu, J., Chen, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12403 · Cited by 199
“According to previous reports, multiple ubiquitin-conjugating enzymes (ubiquitin ligases) and deubiquitinating enzymes interact and regulate c-Myc degradation via the proteasome system [27, 28].”
BackgroundGouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A., Hsieh, A. L., Sullivan, D. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.012 · Cited by 200
“Note that both activated KRAS and BCR-ABL are reported to depend on and increase MYC activity (Afar et al., 1994; Farrell and Sears, 2014; Kimmelman, 2015; Sawyers et al., 1992; Sears et al., 1999; Ying et al., 2012).”
BackgroundCRY2 and FBXL3 Cooperatively Degrade c-MYC
Huber, A.-L., Papp, S. J., Chan, A. B., Henriksson, E., Jordan, S. D., Kriebs, A., Nguyen, M., Wallace, M., Li, Z., Metallo, C. M., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.012 · Cited by 195
“c-MYCplays a critical role in cell proliferation, and its levels are tightly controlled by regulated protein degradation (Farrell and Sears, 2014).”
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G., Azam, S. H., Ozkan-Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187
“Indirect pharmacologic activation of PP2A can decrease pS62, increasing MYC degradation {Farrell, 2014 #32}.”
BackgroundSelective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
“Moreover, MBII is involved in Myc protein turnover as is a docking site for SKP2, the E3 ubiquitin ligase component S-phase kinase-associated protein 2 that, in addition to FBW7, is involved in the degradation of Myc [44,45].”
BackgroundInfluentialDong, H., Adams, N. M., Xu, Y., Cao, J., Allan, D. S. J., Carlyle, J. R., Chen, X., Sun, J. C., & Glimcher, L. H. (2019) · Nature Immunology · doi:10.1038/s41590-019-0388-z · Cited by 172
Das, S. K., Lewis, B. A., & Levens, D. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.07.006 · Cited by 160
MYC protein stability is negatively regulated by BRD4
Devaiah, B. N., Mu, J., Akman, B., Uppal, S., Weissman, J. D., Cheng, D., Baranello, L., Nie, Z., Levens, D., & Singer, D. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919507117 · Cited by 165
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Kim, D., Hong, A., Park, H. I., Shin, W. H., Yoo, L., Jeon, S. J., & Chung, K. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25841 · Cited by 158
“…example, c-Myc overexpression is associated with various human cancers, including breast cancer (Ren et al., 2013), NSCLC (Rapp et al., 2009), and prostate cancer (Fan et al., 2016). c-Myc stability is regulated primarily by the ubiquitin-proteasome system (Farrell & Sears, 2014; Sun et al., 2015).”
BackgroundMission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 156
Self-citationStabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
“Myc 74 is highly regulated and degrades rapidly (Farrell and Sears, 2014), so a dynamic equilibrium shift 75 away from Myc/Max transcriptional activation can occur by inhibiting the Myc/Max interaction 76 directly or by inducing either Max/Max homodimers or Max/Mxd heterodimers (Conacci-Sorrell 77 et al.”
BackgroundProteomic profiling of VCP substrates links VCP to K6‐linked ubiquitylation and c‐Myc function
Heidelberger, J. B., Voigt, A., Borisova, M. E., Petrosino, G., Ruf, S., Wagner, S., & Beli, P. (2018) · EMBO Reports · doi:10.15252/embr.201744754 · Cited by 147
“…factor c-Myc are extensively regulated by dynamic ubiquitylation and deubiquitylation that is mediated by a number of ubiquitin ligases and deubiquitylating enzymes [59]. c-Myc binds chromatin only after forming a heterodimer with Max and activates the transcription of many genes [78 – 80].”
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
Jiang, J., Wang, J., Yue, M., Cai, X., Wang, T., Wu, C., Su, H., Wang, Y., Han, M., Zhang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.001 · Cited by 140
“Rapid protein degradation by the ubiquitin-proteasome system is an essential mechanism responsible for tight control of physiological levels of MYC (Farrell and Sears, 2014).”
BackgroundTargeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 140
“MYC is a critical driver of KrasG12D-dependent up-regulation of genes that support the increased glycolytic and metabolic needs of pancreatic tumors[84] and ERK phosphorylation of MYC prevents MYC protein degradation[85].”
BackgroundZhang, P., Cao, L., Fan, P., Mei, Y., & Wu, M. (2016) · EMBO Reports · doi:10.15252/embr.201642067 · Cited by 126
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 139
Geng, C., Kaochar, S., Li, M., Rajapakshe, K., Fiskus, W. C., Dong, J., Foley, C., Dong, B., Zhang, L., Kwon, O.-J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.80 · Cited by 125
Roles for MYC in the Establishment and Maintenance of PluripotencyPreprint
Chappell, J., & Dalton, S. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014381 · Cited by 123
MYC Controls the Epstein-Barr Virus Lytic Switch
Guo, R., Jiang, C., Zhang, Y., Govande, A. A., Trudeau, S. J., Chen, F., Fry, C. J., Puri, R., Wolinsky, E., Schineller, M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.03.025 · Cited by 119
“Notably, MYCm RNA and protein are highly labile, with half-lives of 20–30 minutes (Farrell and Sears, 2014).”
BackgroundSun, Y., Bell, J. L., Carter, D. R., Gherardi, S., Poulos, R. C., Milazzo, G., Wong, J. W. H., Al‐awar, R., Tee, A. E., Liu, P. Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0423 · Cited by 125
The Role of MIZ-1 in MYC-Dependent TumorigenesisPreprint
Wiese, K. E., Walz, S., von Eyß, B., Wolf, E., Athineos, D., Sansom, O. J., & Eilers, M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014290 · Cited by 130
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 127
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase
Herold, S., Kalb, J., Büchel, G., Ade, C. P., Baluapuri, A., Xu, J., Köster, J., Solvie, D., Carstensen, A., Klotz, C., et al. (2019) · Nature · doi:10.1038/s41586-019-1030-9 · Cited by 123
Jaenicke, L. A., von Eyß, B., Carstensen, A., Wolf, E., Xu, W., Greifenberg, A. K., Geyer, M., Eilers, M., & Popov, N. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.007 · Cited by 123
“MYCprotein levels and activity are stringently controlled by the ubiquitin-proteasome system (Farrell and Sears, 2014).”
BackgroundInfluentialChen, J., Ding, C., Chen, Y., Hu, W., Lu, Y., Wu, W., Zhang, Y., Yang, B., Wu, H., Peng, C., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0226-z · Cited by 107
Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma
Gu, Y., Zhang, J., Ma, X., Kim, B.-W., Wang, H., Li, J., Pan, Y., Xu, Y., Ding, L., Yang, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.001 · Cited by 107
“Previous studies have demonstrated that alteration of S62 and T58 phosphorylation levels with consequent increased c-Myc stability in tumors could explain the observed c-Myc overexpression in the absence of gene amplification (Farrell and Sears, 2014).”
C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target
Chanvorachote, P., Sriratanasak, N., & Nonpanya, N. (2020) · Anticancer Research · doi:10.21873/anticanres.13990 · Cited by 114
MYC function and regulation in physiological perspective
Jha, R., Kouzine, F., & Levens, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1268275 · Cited by 126
“MYC box I controls its proteasome mediated degradation of MYC proteins (Farrell and Sears, 2014).”
BackgroundMYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 113
Ngai, D., Schilperoort, M., & Tabas, I. A. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00921-9 · Cited by 112
“Together, these data show that EIL drives Myc production and EIMP, but there is an upper limit to the concentration of lactic acid that can promote this process.”
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Krishnamoorthy, G. P., Davidson, N. R., Leach, S. D., Zhao, Z., Lowe, S. W., Lee, G., Landa, I., Nagarajah, J., Saqcena, M., Singh, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0606 · Cited by 94
“Oncogenic RAS acts via ERK to prevent c-MYC degradation, primarily through phosphorylation of serine 62, a site within the c-MYC degron recognized by a specific E3 ubiquitin ligase (49, 50).”
BackgroundSUMO protease SENP1 deSUMOylates and stabilizes c-Myc
Sun, X., Chen, Y., Su, Y., Wang, X., Chauhan, K. M., Liang, J. B., Daniel, C. J., Sears, R. C., & Dai, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802932115 · Cited by 93
“Likewise, c-Myc is regulated by a number of other ubiquitin ligases such as SCFSkp2, SCFβTRCP, and HUWE1 (4, 10), as well as deubiquitinating enzymes (DUBs), including the ubiquitin-specific protease (USP) family members USP28, USP36, USP37, USP13, and USP22 (10–14).”
BackgroundSelf-citationThe transcriptional landscape of Shh medulloblastoma
Skowron, P., Farooq, H., Cavalli, F. M. G., Morrissy, A. S., Ly, M., Hendrikse, L. D., Wang, E. Y., Djambazian, H. H. V., Zhu, H., Mungall, K. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21883-0 · Cited by 103
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
Ren, Y., Bi, C., Zhao, X., Lwin, T., Wang, C., Ji, Y., Silva, A. S., Shah, B. D., Fang, B., Li, T., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122533 · Cited by 91
MYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 100
“A number of E3 ubiquitin ligases have been implicated in ubiquitylation of MYC, including SKP2, FBXW7, HUWE1/HECTH9, FBX29, βTRCP, TRUSS, PIRH2, FBXO28, CHIP and FBXL14 (for review see [40,44]).”
BackgroundMolecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 102
FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity
Mei, Z., Zhang, D., Hu, B., Wang, J., Shen, X., & Xiao, W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645978 · Cited by 88
Close, V., Close, W., Kugler, S. J., Reichenzeller, M., Yosifov, D. Y., Bloehdorn, J., Pan, L., Tausch, E., Westhoff, M., Döhner, H., et al. (2018) · Blood · doi:10.1182/blood-2018-09-874529 · Cited by 96
Lin, K., Rutter, J. C., Xie, A., Pardieu, B., Winn, E. T., Bello, R. D., Forget, A., Itzykson, R., Ahn, Y.-R., Dai, Z., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0590-9 · Cited by 97
Samuels, T. J., Järvelin, A. I., Ish‐Horowicz, D., & Davis, I. (2020) · eLife · doi:10.7554/elife.51529 · Cited by 82
Zeleke, T. Z., Pan, Q., Chiuzan, C. C., Onishi, M., Li, Y., Tan, H., Alvarez, M. J., Honan, E., Yang, M., Chia, P. L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00489-5 · Cited by 90
Concepts to Target MYC in Pancreatic Cancer
Wirth, M., Mahboobi, S., Krämer, O. H., & Schneider, G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0050 · Cited by 84
“Protein stability of MYC is regulated by tightly connected phosphorylation/dephosphorylation events, which are connected to ubiquitination/deubiquitination cycles (59).”
BackgroundRavichandran, M., Hu, J., Cai, C., Ward, N. P., Venida, A., Foakes, C., Kuljanin, M., Yang, A., Hennessey, C. J., Yang, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0044 · Cited by 80
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Koh, C. M., Sabò, A., & Guccione, E. (2016) · BioEssays · doi:10.1002/bies.201500134 · Cited by 102
“The stability and turnover of the MYC protein is regulated by a series of post-translational modifications that are controlled by a myriad of proteins [83].”
BackgroundKing, B., Boccalatte, F. E., Moran-Crusio, K., Wolf, E., Wang, J., Kayembe, C., Lazaris, C., Yu, X., Aranda-Orgillés, B., Lasorella, A., et al. (2016) · Nature Immunology · doi:10.1038/ni.3559 · Cited by 91
Porter, J. R., Fisher, B. E., Baranello, L., Liu, J. C., Kambach, D. M., Nie, Z., Koh, W. S., Luo, J., Stommel, J. M., Levens, D., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.028 · Cited by 84
“In particular, degradation of MYC results from the activity of many E3 ubiquitin ligases (Farrell and Sears, 2014).”
Sang, B., Zhang, Y. Y., Guo, S., Kong, L. F., Cheng, Q., Liu, G., Thorne, R. F., Zhang, X. D., Jin, L., & Wu, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805950115 · Cited by 84
“Of note, c-Myc protein is well known to be ubiquitinated and degraded via complexes containing the FBXW7 or SKP2 E3 ligase (68).”
Manjunath, H., Zhang, H., Rehfeld, F., Han, J., Chang, T.-C., & Mendell, J. T. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.129 · Cited by 78
“, 1983) to the continuous degradation of MYC protein (Farrell and Sears, 2014; Sears, 2004).”
BackgroundTranscriptional Regulation in Prostate Cancer.Preprint
Labbé, D., & Brown, M. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030437 · Cited by 67
BRD4 and MYC : power couple in transcription and disease
Kotekar, A., Singh, A. K., & Devaiah, B. N. (2022) · FEBS Journal · doi:10.1111/febs.16580 · Cited by 80
“…at Thr-58, Pin1 reverses proline 63 isomerization from cis to trans to facilitate protein phosphatase 2A (PP2A)- mediated dephosphorylation of Ser-62, leaving only the pT58 mark that is then recognised by the SCF Fbw7 E3 ubiquitin ligase and degraded by the 26S proteasome [75,78,79].”
BackgroundMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
“153,154 The KRAS-ERK axis can activate the inhibitor of apoptosis protein Survivin to inhibit both MYC autophagic degradation and its dephosphorylation through a CIP2A-dependent inhibition of PP2A.”
BackgroundGe, J., Yu, W., Li, J., Ma, H., Wang, P., Zhou, Y., Wang, Y., Zhang, J., & Shi, G. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01843-8 · Cited by 79
“MYC is a short-lived protein and its stability is precisely regulated by the ubiquitin-proteasome system[17].”
BackgroundBlake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 72
The functions and mechanisms of prefoldin complex and prefoldin-subunits
Liang, J., Xia, L., Oyang, L., Lin, J., Tan, S., Yi, P., Han, Y., Luo, X., Wang, H. Z., Tang, L., et al. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00446-8 · Cited by 74
An early Myc‐dependent transcriptional program orchestrates cell growth during B‐cell activation
Tesi, A., de Pretis, S., Furlan, M., Filipuzzi, M., Morelli, M. J., Andronache, A., Doni, M., Verrecchia, A., Pelizzola, M., Amati, B. B., et al. (2019) · EMBO Reports · doi:10.15252/embr.201947987 · Cited by 77
“RNA-Seq and ChIP-Seq data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE126340 (https://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE126340).”
Dissecting transcriptional amplification by MYC
Nie, Z., Guo, C., Das, S., Chow, C. C., Batchelor, E., Simons, S. S., & Levens, D. (2020) · eLife · doi:10.7554/elife.52483 · Cited by 69
Marampon, F., Ciccarelli, C., & ZANI, B. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102530 · Cited by 75
“The level of Myc is regulated by two kinases: ERK phosphorylates Ser62 and stabilizes Myc, thereby enabling the latter to act at the promoters of growth and transformation genes, whereas GSK3-beta phosphorylates Myc at Thr58, thereby promoting the ubiquitination and degradation of Myc after protein complex formation a…”
BackgroundTargeting MYC Proteins for Tumor Therapy
Wolf, E., & Eilers, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055826 · Cited by 68
RNF4-Dependent Oncogene Activation by Protein Stabilization
Thomas, J. J., Abed, M., Heuberger, J., Novak, R., Zohar, Y., López, Á. P. B., Trausch‐Azar, J. S., Ilagan, M. X. G., Benhamou, D., Dittmar, G. A. G., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.024 · Cited by 63
“Ser62 phosphorylation also primes c-Myc for GSK3-dependent phosphorylation of Thr58 that subsequently marks it for degradation (Welcker et al., 2004; Farrell and Sears, 2014).”
BackgroundDingar, D. D., Tu, W. B., Resetca, D., Lourenco, C., Tamachi, A., Melo, J. D., Houlahan, K. E., Kalkat, M., Chan, P.-K., Boutros, P. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05660-0 · Cited by 66
Shavlakadze, T., Zhu, J., Wang, S., Zhou, W., Morin, B., Egerman, M. A., Fan, L., Wang, Y., Iartchouk, O., Meyer, A., et al. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx249 · Cited by 59
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Tarrado‐Castellarnau, M., de Atauri, P., Tarragó‐Celada, J., Perarnau, J., Yuneva, M. O., Thomson, T. M., & Cascante, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167321 · Cited by 65
“Consistent with the known ubiquitin – proteasome-dependent turnover of MYC (Farrell & Sears, 2014), its relatively low levels in control cells were upregulated by treatment with the proteasome inhibitor MG132 (Fig 5A).”
Writing and erasing MYC ubiquitination and SUMOylation
Chen, Y., Sun, X., Sears, R. C., & Dai, M. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.05.006 · Cited by 65
“Two important phosphorylation sites, Threonine 58 (T58) and Serine 62 (S62) lie in MBI, involved in regulation of MYC stability and activity in response to cell growth signals.(1,2,12,13) The central region of MYC contains the MBIII and MBIV which are both important for MYC’s pro-apoptotic activity as well as for tran…”
BackgroundSelf-citationMuto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 62
“Despite evidence of interplay between acetylation and ubiquitination of MYC, the consequences of these modifications and specifically the role of non-degradative ubiquitination on MYC function and relevance to cancer are not well understood(Farrell and Sears, 2014).”
Cellular MYCro Economics: Balancing MYC Function with MYC Expression
Levens, D. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014233 · Cited by 60
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma
Ecker, J., Thatikonda, V., Sigismondo, G., Selt, F., Valinciute, G., Oehme, I., Müller, C., Buhl, J. L., Ridinger, J., Usta, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa191 · Cited by 60
Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor
Welcker, M., Wang, B., Rusnac, D.-V., Hussaini, Y., Swanger, J., Zheng, N., & Clurman, B. E. (2022) · Science Advances · doi:10.1126/sciadv.abl7872 · Cited by 58
Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity
Helander, S., Montecchio, M., Pilstål, R., Su, Y., Kuruvilla, J., Elvén, M., Ziauddin, J. M. E., Anandapadamanaban, M., Cristóbal, S., Lundström, P., et al. (2015) · Structure · doi:10.1016/j.str.2015.10.010 · Cited by 62
“…acting on trans substrates (Brown et al., 1999; Lu et al., 2002a) and phosphatases, which control the pathway of c-Myc activation and ubiquitin-mediated degradation (Figure 1A) (Farrell and Sears, 2014; Sears, 2004), and which have been shown to act on cis substrates (Werner-Allen et al., 2011).”
BackgroundSelf-citationQiao, X., Liu, Y., Prada, M. L., Mohan, A. K., Gupta, A., Jaiswal, A., Sharma, M., Merisaari, J., Haikala, H. M., Talvinen, K., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1647 · Cited by 56
“org Cancer Res; 80(7) April 1, 2020 1417”
BackgroundInfluentialThe OGT–c-Myc–PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth
Wang, H., Sun, J., Sun, H., Wang, Y., Lin, B., Wu, L., Qin, W., Zhu, Q., & Yi, W. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01315-4 · Cited by 68
“For example, poly-ubiquitination of c-Myc by the E3 ligases FBXW7, HectH9, TRIM32 and MAGI3 promotes c-Myc degradation, while USP28 antagonizes the above process [38, 39].”
Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins
Habib, J. A., Plaen, E. D., Stroobant, V., Živković, D., Bousquet, M., Guillaume, B., Wahni, K., Messens, J., Busse, A., Vigneron, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71550-5 · Cited by 66
Max deletion destabilizes MYC protein and abrogates Eµ- Myc lymphomagenesis
Mathsyaraja, H., Freie, B., Cheng, P.-F., Babaeva, E., Catchpole, J. T., Janssens, D., Henikoff, S., & Eisenman, R. N. (2019) · Genes & Development · doi:10.1101/gad.325878.119 · Cited by 54
“The rate of MYC protein degradation is mediated by several factors that interfere with signals triggering MYC ubiquitination and proteasomal degradation (Farrell and Sears 2014).”
BackgroundPARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy
Yu, M., Chen, Z., Zhou, Q., Zhang, B., Huang, J., Jin, L., Zhou, B., Liu, S., Yan, J., Li, X., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.026 · Cited by 54
Transposable element exonization generates a reservoir of evolving and functional protein isoforms
Arribas, Y. A., Baudon, B., Rotival, M., Suárez, G., Bonté, P., Casas, V., Roubert, A., Klein, P., Bonnin, E., Mchich, B., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.011 · Cited by 66
“28 28–31 As control for stable proteins, lamin B1 is highly stable across the evaluated time points 28 (Figures 4B, top, and S4A).”
Chen, P., Yang, W., Hong, T., Miyazaki, T., Dirisala, A., Kataoka, K., & Cabral, H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121748 · Cited by 51
Regulation of c-Myc protein stability by proteasome activator REGγ
Li, S., Jiang, C., Pan, J., Wang, X., Jin, J., Zhao, L., Pan, W., Liao, G., Cai, X., Li, X., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.188 · Cited by 52
Chen, W. S., Liang, Y., Zong, M., Liu, J. J., Kaneko, K., Hanley, K. L., Zhang, K., & Feng, G.-S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109974 · Cited by 50
“Although the complex mechanisms of Myc activation remain to be fully elucidated, phosphorylation of Myc at S62 by Erk was shown to promote its stability and activity (Farrell and Sears, 2014; Hayes et al., 2016).”
BackgroundMethodMYC in liver cancer: mechanisms and targeted therapy opportunities
Liu, F., Liao, Z., & Zhang, Z. (2023) · Oncogene · doi:10.1038/s41388-023-02861-w · Cited by 60
Circadian regulation of c-MYC in mice
Liu, Z., Selby, C. P., Yang, Y., Lindsey‐Boltz, L. A., Cao, X., Eynullazada, K., & Sancar, A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011225117 · Cited by 56
Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors
Truica, M. I., Burns, M. C., Han, H., & Abdulkadir, S. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2959 · Cited by 53
Metadata
- Authors
- Farrell, A. S., & Sears, R. C.
- Affiliations
- Oregon Health & Science University (US)
- ORCID
- Sears, R. C.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-03-01
- Volume
- 4
- Issue
- 3
- Pages
- a014365-a014365
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3935390
- OpenAlex
- W4236967220
- Cited by
- 468
- References
- 114
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 46 · 2023: 58 · 2022: 58 · 2021: 53 · 2020: 55 · 2019: 29 · 2018: 28 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 10
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- Myc oncoprotein, protein degradation, ubiquitin-proteasome system, MYC protein stability, transcriptional regulation, cancer, MYC-targeted therapy, cell proliferation
- MeSH terms
- Acetylation, Cell Communication, Humans, Neoplasms, Transcription, Genetic, Genes, myc, Ubiquitin, Proteasome Endopeptidase Complex, Protein Stability, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.